Until 2010 dba Knopp Nuerosciences, Knopp Biosciences is advancing novel agents to activate a key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as epilepsy and neuropathic pain. Focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, in addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp directs its preclinical Kv7 platform to small molecule treatments for KCNQ2 epileptic encephalopathy and other CNS hyperexcitability disorders, Knopp Biosciences is also organized around the firm's Mitochondrial Discovery Program - mitochondrion being the powerhouse of the cell, providing energy to every cell type in the body. Brain cells rank among the most energy-demanding cells in the body. The disruption of cellular bioenergetic activity has emerged as a common factor in multiple pathways leading to nerve cell death in diseases such as ALS, Parkinson's and other neurodegenerative disorders.
